Pay in 4 interest-free payments of $6.58 Learn more
Ships within 48 hours · Estimated delivery Aug 6 - Aug 11
Maier EM, Liebl B, Roschinger W, Nennstiel-Ratzel U, Fingerhut R, Olgemoller B, et al
Patients with Hepatic Impairment Dulaglutide systemic exposure decreased by 23, 33 and 21% for mild, moderate and severe hepatic impairment groups, respectively, compared to subjects with normal hepatic function, and Cmax was decreased by a similar magnitude (Figure 1) [see Use in Specific Populations (8.7)]
The study has not yet been published in a peer-reviewed scientific journal, but was presented at the European Congress on Obesity (ECO2026) from May 1215
To help readers manage their caffeine intake while using semaglutide, we offer practical advice, including recommended daily limits and strategies to minimize negative interactions
US$ 23.07
US$ 27.75
US$ 23.78
